Want to see SNPHY full AI Analyst Report?
Santen Pharmaceutical Co (SNPHY) Ratios
Santen Pharmaceutical Co Ratios
SNPHY's free cash flow for Q1 2026 was $40.58M. For the 2026 fiscal year, SNPHY's free cash flow was decreased by $-12.85M and operating cash flow was $53.43M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.58 | 2.60 | 2.54 | 2.38 | 2.39 |
| Quick Ratio | 1.99 | 1.87 | 2.08 | 1.94 | 2.01 |
| Cash Ratio | 1.07 | 0.92 | 1.02 | 0.65 | 0.87 |
| Solvency Ratio | 0.36 | 0.46 | 0.34 | 0.02 | 0.36 |
| Operating Cash Flow Ratio | 0.70 | 0.52 | 0.78 | 0.42 | 0.48 |
| Short-Term Operating Cash Flow Coverage | 222.36 | 150.73 | 1345.35 | 151.62 | 4.21 |
| Net Current Asset Value | $ 100.20B | $ 102.18B | $ 105.81B | $ 85.44B | $ 106.29B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.08 | 0.08 | 0.09 | 0.07 |
| Debt-to-Equity Ratio | 0.12 | 0.12 | 0.11 | 0.12 | 0.10 |
| Debt-to-Capital Ratio | 0.11 | 0.10 | 0.10 | 0.11 | 0.09 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.08 | 0.08 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.43 | 1.42 | 1.42 | 1.43 | 1.36 |
| Debt Service Coverage Ratio | 15.85 | 23.52 | 17.49 | 2.16 | 3.66 |
| Interest Coverage Ratio | 17.26 | 22.68 | 14.47 | -2.06 | 29.68 |
| Debt to Market Cap | 0.00 | 0.05 | 0.05 | 0.00 | 0.02 |
| Interest Debt Per Share | 105.98 | 112.99 | 103.09 | 97.33 | 85.40 |
| Net Debt to EBITDA | -1.00 | -0.69 | -1.17 | -1.68 | -0.95 |
| Profitability Margins | |||||
| Gross Profit Margin | 57.01% | 55.20% | 59.18% | 59.52% | 58.81% |
| EBIT Margin | 16.73% | 15.50% | 10.78% | -1.54% | 13.47% |
| EBITDA Margin | 19.67% | 21.80% | 16.80% | 4.64% | 19.88% |
| Operating Profit Margin | 15.63% | 15.50% | 12.76% | -1.11% | 13.48% |
| Pretax Profit Margin | 15.83% | 16.27% | 9.89% | -2.08% | 13.38% |
| Net Profit Margin | 12.09% | 12.81% | 8.82% | -5.36% | 10.22% |
| Continuous Operations Profit Margin | 11.95% | 12.88% | 8.84% | -5.37% | 10.21% |
| Net Income Per EBT | 76.36% | 78.77% | 89.18% | 257.77% | 76.42% |
| EBT Per EBIT | 101.28% | 104.93% | 77.51% | 187.67% | 99.25% |
| Return on Assets (ROA) | 8.86% | 9.33% | 6.11% | -3.55% | 5.92% |
| Return on Equity (ROE) | 12.67% | 13.28% | 8.70% | -5.08% | 8.06% |
| Return on Capital Employed (ROCE) | 14.54% | 14.24% | 11.24% | -0.93% | 9.85% |
| Return on Invested Capital (ROIC) | 10.87% | 11.16% | 9.97% | -0.92% | 7.25% |
| Return on Tangible Assets | 10.86% | 11.23% | 7.57% | -4.60% | 8.25% |
| Earnings Yield | 7.32% | 6.85% | 5.11% | -3.44% | 5.61% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.18 | 4.29 | 3.34 | 2.60 | 2.67 |
| Payables Turnover | 3.31 | 3.90 | 2.83 | 2.51 | 2.66 |
| Inventory Turnover | 2.50 | 2.14 | 2.85 | 2.87 | 2.95 |
| Fixed Asset Turnover | 4.11 | 3.94 | 4.22 | 4.22 | 4.73 |
| Asset Turnover | 0.73 | 0.73 | 0.69 | 0.66 | 0.58 |
| Working Capital Turnover Ratio | 2.14 | 2.22 | 2.26 | 2.17 | 2.04 |
| Cash Conversion Cycle | 122.97 | 162.52 | 108.41 | 122.11 | 123.07 |
| Days of Sales Outstanding | 87.31 | 85.16 | 109.44 | 140.18 | 136.52 |
| Days of Inventory Outstanding | 146.00 | 170.90 | 127.88 | 127.17 | 123.61 |
| Days of Payables Outstanding | 110.34 | 93.54 | 128.91 | 145.24 | 137.07 |
| Operating Cycle | 233.30 | 256.06 | 237.32 | 267.35 | 260.14 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 174.78 | 140.78 | 198.01 | 95.88 | 115.17 |
| Free Cash Flow Per Share | 155.67 | 118.63 | 168.88 | 32.42 | 25.52 |
| Dividend Paid and CapEx Coverage Ratio | 3.25 | 2.23 | 3.22 | 1.00 | 0.96 |
| Capital Expenditure Coverage Ratio | 9.15 | 6.36 | 6.80 | 1.51 | 1.28 |
| Operating Cash Flow Coverage Ratio | 1.78 | 1.32 | 2.07 | 1.03 | 1.40 |
| Operating Cash Flow to Sales Ratio | 0.20 | 0.15 | 0.24 | 0.13 | 0.17 |
| Free Cash Flow Yield | 10.96% | 6.72% | 11.89% | 2.89% | 2.10% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 13.66 | 14.53 | 19.57 | -29.10 | 17.83 |
| Price-to-Sales (P/S) Ratio | 1.65 | 1.87 | 1.73 | 1.56 | 1.82 |
| Price-to-Book (P/B) Ratio | 1.73 | 1.94 | 1.70 | 1.48 | 1.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 9.12 | 14.88 | 8.41 | 34.64 | 47.58 |
| Price-to-Operating Cash Flow Ratio | 8.12 | 12.54 | 7.18 | 11.71 | 10.54 |
| Price-to-Earnings Growth (PEG) Ratio | 0.32 | 0.87 | -0.07 | 0.19 | 0.06 |
| Enterprise Value Multiple | 7.39 | 7.89 | 9.11 | 31.92 | 8.22 |
| Enterprise Value | 436.26B | 531.89B | 461.88B | 413.33B | 435.28B |
| EV to EBITDA | 7.39 | 7.89 | 9.11 | 31.92 | 8.22 |
| EV to Sales | 1.45 | 1.72 | 1.53 | 1.48 | 1.63 |
| EV to Free Cash Flow | 8.04 | 13.68 | 7.45 | 32.91 | 42.67 |
| EV to Operating Cash Flow | 7.16 | 11.53 | 6.36 | 11.13 | 9.45 |
| Tangible Book Value Per Share | 601.58 | 687.78 | 603.86 | 508.46 | 516.86 |
| Shareholders’ Equity Per Share | 821.11 | 910.43 | 834.19 | 758.81 | 844.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.24 | 0.21 | 0.11 | -1.58 | 0.24 |
| Revenue Per Share | 860.58 | 943.80 | 823.04 | 720.24 | 666.02 |
| Net Income Per Share | 104.00 | 120.94 | 72.62 | -38.58 | 68.08 |
| Tax Burden | 0.76 | 0.79 | 0.89 | 2.58 | 0.76 |
| Interest Burden | 0.95 | 1.05 | 0.92 | 1.35 | 0.99 |
| Research & Development to Revenue | 0.08 | 0.09 | 0.08 | 0.10 | 0.10 |
| SG&A to Revenue | 0.29 | 0.31 | 0.30 | 0.34 | 0.32 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.68 | 1.16 | 2.73 | -2.48 | 1.69 |
Currency in JPY
